143 related articles for article (PubMed ID: 29108288)
21. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
22. Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib.
Stoeva V; Petrova G; Mitov K; Tachkov K
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513888
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Gupta V; Yacoub A; Mesa RA; Harrison CN; Vannucchi AM; Kiladjian JJ; Deeg HJ; Fazal S; Foltz L; Mattison RJ; Miller CB; Parameswaran V; Brown P; Hernandez C; Wang J; Talpaz M
Leuk Lymphoma; 2024 Jun; ():1-11. PubMed ID: 38838026
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Shanavas M; Popat U; Michaelis LC; Fauble V; McLornan D; Klisovic R; Mascarenhas J; Tamari R; Arcasoy MO; Davies J; Gergis U; Ukaegbu OC; Kamble RT; Storring JM; Majhail NS; Romee R; Verstovsek S; Pagliuca A; Vasu S; Ernst B; Atenafu EG; Hanif A; Champlin R; Hari P; Gupta V
Biol Blood Marrow Transplant; 2016 Mar; 22(3):432-40. PubMed ID: 26493563
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.
Hernández-Boluda JC; Correa JG; García-Delgado R; Martínez-López J; Alvarez-Larrán A; Fox ML; García-Gutiérrez V; Pérez-Encinas M; Ferrer-Marín F; Mata-Vázquez MI; Raya JM; Estrada N; García S; Kerguelen A; Durán MA; Albors M; Cervantes F
Eur J Haematol; 2017 Apr; 98(4):407-414. PubMed ID: 28009442
[TBL] [Abstract][Full Text] [Related]
26. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
Cervantes F; Isola IM; Alvarez-Larrán A; Hernández-Boluda JC; Correa JG; Pereira A
Ann Hematol; 2015 Nov; 94(11):1791-6. PubMed ID: 26122869
[TBL] [Abstract][Full Text] [Related]
27. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
Patnaik MM; Caramazza D; Gangat N; Hanson CA; Pardanani A; Tefferi A
Eur J Haematol; 2010 Feb; 84(2):105-8. PubMed ID: 19895568
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib-associated infections: A systematic review and meta-analysis.
Lussana F; Cattaneo M; Rambaldi A; Squizzato A
Am J Hematol; 2018 Mar; 93(3):339-347. PubMed ID: 29150886
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Polverelli N; Palumbo GA; Binotto G; Abruzzese E; Benevolo G; Bergamaschi M; Tieghi A; Bonifacio M; Breccia M; Catani L; Tiribelli M; D'Adda M; Sgherza N; Isidori A; Cavazzini F; Martino B; Latagliata R; Crugnola M; Heidel F; Bosi C; Ibatici A; Soci F; Penna D; Scaffidi L; Aversa F; Lemoli RM; Vitolo U; Cuneo A; Russo D; Cavo M; Vianelli N; Palandri F
Hematol Oncol; 2018 Apr; ():. PubMed ID: 29624703
[TBL] [Abstract][Full Text] [Related]
30. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
Salit RB; Deeg HJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
[TBL] [Abstract][Full Text] [Related]
33. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.
Palandri F; Palumbo GA; Bonifacio M; Breccia M; Latagliata R; Martino B; Polverelli N; Abruzzese E; Tiribelli M; Nicolosi M; Bergamaschi M; Tieghi A; Iurlo A; Sgherza N; Cavazzini F; Isidori A; Binotto G; Ibatici A; Crugnola M; Heidel F; Bosi C; Bartoletti D; Auteri G; Catani L; Cuneo A; Aversa F; Semenzato G; Cavo M; Vianelli N; Benevolo G
Leuk Res; 2018 Nov; 74():86-88. PubMed ID: 30321784
[No Abstract] [Full Text] [Related]
34. Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.
Palandri F; Benevolo G; Iurlo A; Abruzzese E; Carella AM; Paoli C; Palumbo GA; Bonifacio M; Cilloni D; Andriani A; Guarini A; Turri D; Elli EM; Falcone A; Anaclerico B; Musto P; Di Renzo N; Tiribelli M; Zambello R; Spinosa C; Ricco A; Raucci L; Martino B; Annunziata M; Pascale S; Liberati AM; La Nasa G; Maffioli M; Breccia M; Pugliese N; Betti S; Giglio G; Cappuccio A; Reale L
Qual Life Res; 2018 Jun; 27(6):1545-1554. PubMed ID: 29520559
[TBL] [Abstract][Full Text] [Related]
35. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
[TBL] [Abstract][Full Text] [Related]
36. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
37. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Gupta V; Griesshammer M; Martino B; Foltz L; Tavares R; Al-Ali HK; Giraldo P; Guglielmelli P; Lomaia E; Bouard C; Paley C; Tiwari R; Zor E; Raanani P
Leuk Lymphoma; 2021 Apr; 62(4):918-926. PubMed ID: 33210570
[TBL] [Abstract][Full Text] [Related]
38. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
39. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
40. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.
Vallapureddy RR; Mudireddy M; Penna D; Lasho TL; Finke CM; Hanson CA; Ketterling RP; Begna KH; Gangat N; Pardanani A; Tefferi A
Blood Cancer J; 2019 Jan; 9(2):12. PubMed ID: 30683837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
